source
- FDA warns Houston compounding pharmacy of unsanitary GLP-1 production risking contaminationFDA issued a warning letter to Empower Clinic Services, operating as Empower Pharmacy, after inspectors found unsanitary conditions at its Houston compounding site. Inspectors observed that the ph…
- Acadia’s Alzheimer’s psychosis drug misses primary goal but advances on secondary dataAcadia Pharmaceuticals reported that its investigational drug remlifanserin failed to meet the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer’s disease psychosis. The t…